You are viewing an incomplete version of our website. Please click to reload the website as full version.

MAPT antibody (Microtubule-Associated Protein tau)

Details for Product anti-MAPT Antibody No. ABIN967155, Supplier: Log in to see
Antigen
  • tau
  • xtp
  • MAPT
  • AI426939
  • AI551861
  • AW457082
  • CK1epsilon
  • CKIe
  • KC1epsilon
  • DDPAC
  • FTDP-17
  • MAPTL
  • MSTD
  • MTBT1
  • MTBT2
  • PPND
  • TAU
  • AI413597
  • AW045860
  • Mtapt
  • Tau
  • PHF-tau
  • RNPTAU
  • pTau
Alternatives
anti-Human MAPT antibody for Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections)
Reactivity
Human, Mouse (Murine), Rat (Rattus)
966
466
444
76
21
19
17
12
9
5
4
4
3
3
3
3
2
1
1
1
1
1
1
Host
Rabbit
920
98
9
9
Clonality
Polyclonal
Conjugate
This MAPT antibody is un-conjugated
23
8
8
5
4
4
1
1
1
1
1
1
1
1
1
1
1
Application
Immunohistochemistry (IHC)
862
351
308
103
70
69
37
16
14
12
12
12
11
8
4
3
2
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Immunogen The antiserum was produced against synthesized non-phosphopeptide derived from human Tau around the phosphorylation site of serine 235 (P-K-SP-P-S).
Specificity Tau (Ab-235) antibody detects endogenous levels of total Tau protein.
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Alternative Name Tau (MAPT Antibody Abstract)
Pathways MAPK Signaling, Microtubule Dynamics
Application Notes WB: 1:500~1:1000.
Restrictions For Research Use only
Format Liquid
Concentration 100ug/100ul.
Buffer Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 50% glycerol
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Product cited in: Liu, Iqbal, Grundke-Iqbal et al.: "Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta." in: FEBS letters, Vol. 530, Issue 1-3, pp. 209-14, 2002 (PubMed).

Sengupta, Kabat, Novak et al.: "Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules." in: Archives of biochemistry and biophysics, Vol. 357, Issue 2, pp. 299-309, 1998 (PubMed).

Background publications Alonso, Mederlyova, Novak et al.: "Promotion of hyperphosphorylation by frontotemporal dementia tau mutations." in: The Journal of biological chemistry, Vol. 279, Issue 33, pp. 34873-81, 2004 (PubMed).